Accepted Preprint (first posted online 26 November 2013)

    Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models to disease mechanisms

    1. Shaodong Guo
    1. S Guo, Medicine, Texas A&M University HSC, Temple, 76504, United States
    1. Correspondence: Shaodong Guo, Email: sguo{at}medicine.tamhsc.edu

    Abstract

    Insulin resistance is a major underlying mechanism for the 'metabolic syndrome', which is also known as insulin resistance syndrome. Metabolic syndrome is increasing at an alarming rate, becoming a major public and clinical problem worldwide. Metabolic syndrome is represented by a group of interrelated disorders, including obesity, hyperglycemia, hyperlipidemia, and hypertension. It is also a significant risk factor for cardiovascular disease and increased morbidity and mortality. Animal studies demonstrate that insulin and its signaling cascade normally control cell growth, metabolism and survival through activation of mitogen-activated protein kinases (MAPKs) and phosphotidylinositide-3-kinase (PI3K), of which activation of PI-3K-associated with insulin receptor substrate-1 and -2 (IRS1, 2) and subsequent Akt→Foxo1 phosphorylation cascade has a central role in control of nutrient homeostasis and organ survival. Inactivation of Akt and activation of Foxo1, through suppression IRS1 and IRS2 in different organs following hyperinsulinemia, metabolic inflammation, and over nutrition may provide the underlying mechanisms for metabolic syndrome in humans. Targeting the IRS→Akt→Foxo1 signaling cascade will likely provide a strategy for therapeutic intervention in the treatment of type 2 diabetes and its complications. This review discusses the basis of insulin signaling, insulin resistance in different mouse models, and how a deficiency of insulin signaling components in different organs contributes to the feature of the metabolic syndrome. Emphasis will be placed on the role of IRS1, IRS2, and associated signaling pathways that couple to Akt and the forkhead/winged helix transcription factor Foxo1.

    • Received 1 August 2013
    • Received in final form 30 October 2013
    • Accepted 22 November 2013
    • Accepted Preprint first posted online on 26 November 2013

    This Article

    1. J Endocrinol JOE-13-0327
    1. Abstract
    2. All Versions of this Article:
      1. JOE-13-0327v1
      2. 220/2/T1 most recent

    Article Metrics